In the current case, the concurrent presence of CTNNB1, ARID1A, and PIK3CA mutations, which are well-described in endometrioid carcinomas, as well as the absence of germ cell tumor-specific genetic alterations, provides strong molecular evidence that the YST phenotype observed was somatically derived. This evidence concerns the gene ARID1A and endometrioid adenocarcinoma.